Cargando…

Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies

Immunocompromised individuals including patients with hematological malignancies constitute a population at high risk of developing severe disease upon SARS-CoV-2 infection. Protection afforded by vaccination is frequently low and the biology leading to altered vaccine efficacy is not fully understo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergamaschi, Cristina, Pagoni, Maria, Rosati, Margherita, Angel, Matthew, Tzannou, Ifigeneia, Vlachou, Margarita, Darmani, Ismini, Ullah, Amirah, Bear, Jenifer, Devasundaram, Santhi, Burns, Robert, Baltadakis, Ioannis, Gigantes, Stavros, Dimopoulos, Meletios-Athanasios, Pavlakis, George N., Terpos, Evangelos, Felber, Barbara K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174567/ https://www.ncbi.nlm.nih.gov/pubmed/35693807 http://dx.doi.org/10.3389/fimmu.2022.899972

Ejemplares similares

Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster Vaccination
por: Rosati, Margherita, et al.
Publicado: (2022)

Antibody Response to COVID-19 mRNA Vaccine in Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia after Primary Immunization and Booster: Reactivity to the Sars-Cov-2 WT Virus, Delta and Omicron Variants
por: Terpos, Evangelos, et al.
Publicado: (2022)

Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients
por: Bergamaschi, Cristina, et al.
Publicado: (2021)

Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques
por: Rosati, Margherita, et al.
Publicado: (2021)

SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors
por: Terpos, Evangelos, et al.
Publicado: (2021)

Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study
por: Terpos, Evangelos, et al.
Publicado: (2021)

Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection
por: Rosati, Margherita, et al.
Publicado: (2021)

Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients
por: Terpos, Evangelos, et al.
Publicado: (2021)

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222
por: Terpos, Evangelos, et al.
Publicado: (2022)

Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes
por: Watson, Dionysios C., et al.
Publicado: (2018)

Correction: Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes
por: Watson, Dionysios C., et al.
Publicado: (2018)

Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals
por: Terpos, Evangelos, et al.
Publicado: (2021)

Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques
por: Devasundaram, Santhi, et al.
Publicado: (2020)

COVID-19 BNT162b2 mRNA vaccine for patients with type 2 diabetes mellitus
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose
por: Terpos, Evangelos, et al.
Publicado: (2021)

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
por: Terpos, Evangelos, et al.
Publicado: (2022)

Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis
por: Papadopoulos, Dimitris, et al.
Publicado: (2022)

Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Step-dose IL-7 treatment promotes systemic expansion of T cells and alters immune cell landscape in blood and lymph nodes
por: Pandit, Hrishikesh, et al.
Publicado: (2023)

Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques
por: Bergamaschi, Cristina, et al.
Publicado: (2018)

PB2140: ALLOGENEIC STEM CELL TRANSPLANTATION IN RARE T-NHL SUBTYPES: FOCUS ON AITL, MF/SS, HSTCL. A SINGLE BMT-UNIT EXPERIENCE.
por: Tzenou, T., et al.
Publicado: (2022)

Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
por: Terpos, Evangelos, et al.
Publicado: (2021)

Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma
por: Thomopoulos, Thomas P., et al.
Publicado: (2021)

Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
por: Terpos, Evangelos, et al.
Publicado: (2021)

Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals
por: Terpos, Evangelos, et al.
Publicado: (2021)

HIV DNA Vaccine: Stepwise Improvements Make a Difference
por: Felber, Barbara K., et al.
Publicado: (2014)

Nuclear export factor RBM15 facilitates the access of DBP5 to mRNA
por: Zolotukhin, Andrei S., et al.
Publicado: (2009)

Heterodimeric IL-15 regulates the differentiation and survival of different populations of memory T cells and the balance of effector and regulatory cells
por: Pavlakis, George N, et al.
Publicado: (2013)

A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis
por: Pappa, Vasiliki, et al.
Publicado: (2021)

Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Accelerating immune reconstitution after hematopoietic stem cell transplantation
por: Tzannou, Ifigeneia, et al.
Publicado: (2014)

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Patients with type 2 diabetes mellitus present similar immunological response to COVID-19 BNT162b2 mRNA vaccine to healthy subjects: a prospective cohort study
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells
por: Bergamaschi, C, et al.
Publicado: (2015)

P-148: Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, except for those under treatment with anti-BCMA agents
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study
por: Terpos, Evangelos, et al.
Publicado: (2020)

Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10
por: Bergamaschi, Cristina, et al.
Publicado: (2020)

Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients
por: Trougakos, Ioannis P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ihmtcr4qdfca42pbeqbd7qvdcq